随机临床试验:姑息性长期腹腔引流管与大容量腹腔穿刺术治疗肝硬化难治性腹水的比较
这项12周可行性非盲随机对照试验比较长期腹腔引流管与大容量腹腔穿刺术治疗终末期肝病难治性腹水,36例患者随机分组(引流管组17例,穿刺组19例),引流管组住院腹水引流次数、腹水相关费用及住院时间比例更低,但自限性蜂窝织炎/渗漏更常见;研究达到可行性标准,问卷/访谈接受与完成率≥80%。
要点
- 长期腹腔引流管组中位住院腹水引流次数为0次(IQR 0-1),大容量腹腔穿刺组为4次(IQR 3-7)。
- 引流管组腹水相关费用中位数£329(IQR 253-580),低于穿刺组£843(IQR 603-1060)。
- 引流管组自限性蜂窝织炎/渗漏发生率为41%(7/17),穿刺组为11%(2/19);腹膜炎发生率分别为6%(1/17)与11%(2/19)。
核心结论
- REDUCe研究表明长期腹腔引流管用于终末期肝病难治性腹水具有可行性,并初步提示其可接受性、有效性、安全性及减少医疗资源利用。
研究设计与样本
- 12周可行性非盲随机对照试验,比较长期腹腔引流管与大容量腹腔穿刺术,每两周进行家庭访视以完成临床与问卷评估。
- 59例合格患者中36例(61%)被随机分组,长期腹腔引流管组17例,大容量腹腔穿刺组19例。
主要发现
- 随机分组后中位住院腹水引流次数(IQR):长期腹腔引流管组0次(0-1)vs 大容量腹腔穿刺组4次(3-7)。
- 第12周血清白蛋白(g/L):长期腹腔引流管组29(26.5-32.5)vs 大容量腹腔穿刺组30(25-35)。
- 第12周血清肌酐(μmol/L):长期腹腔引流管组104.5(81-115.5)vs 大容量腹腔穿刺组127(63-158)。
- 总脱落率为42%(长期腹腔引流管组47%,大容量腹腔穿刺组37%)。
- 每两周社区/医院/社会照护腹水相关费用中位数(IQR)及腹水相关住院时间百分比:长期腹腔引流管组£329(253-580)与0%(0-0.74),均低于大容量腹腔穿刺组£843(603-1060)与2.75%(2.35-3.84)。
关键数值与推荐
- 研究成功标准为脱落率不超过50%、因并发症移除长期腹腔引流管低于10%、长期腹腔引流管组腹水相关住院时间占比低于50%(较大容量腹腔穿刺组)以及问卷/访谈接受与完成率达80%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Palliative care remains suboptimal in end-stage liver disease. AIM: To inform a definitive study, we assessed palliative long-term abdominal drains in end-stage liver disease to determine recruitment, attrition, safety/potential effectiveness, questionnaires/interview uptake/completion and make a preliminary cost comparison. METHODS: A 12-week feasibility nonblinded randomised controlled trial comparing large-volume paracentesis vs long-term abdominal drains in refractory ascites due to end-stage liver disease with fortnightly home visits for clinical/questionnaire-based assessments. Study success criteria were attrition not >50%, <10% long-term abdominal drain removal due to complications, the long-term abdominal drain group to spend <50% ascites-related study time in hospital vs large-volume paracentesis group and 80% questionnaire/interview uptake/completion. RESULTS: Of 59 eligible patients, 36 (61%) were randomised, 17 to long-term abdominal drain and 19 to large-volume paracentesis. Following randomisation, median number (IQR) of hospital ascitic drains (long-term abdominal drain group vs large-volume paracentesis group) were 0 (0-1) vs 4 (3-7); week 12 serum albumin (g/L) and serum creatinine (μmol/L) were 29 (26.5-32.5) vs 30 (25-35) and 104.5 (81-115.5) vs 127 (63-158) respectively. Total attrition was 42% (long-term abdominal drain group 47%, large-volume paracentesis group 37%). Median (IQR) fortnightly community/hospital/social care ascites-related costs and percentage study time in hospital were lower in the long-term abdominal drain group, £329 (253-580) vs £843 (603-1060) and 0% (0-0.74) vs 2.75% (2.35-3.84) respectively. Self-limiting cellulitis/leakage occurred in 41% (7/17) in the long-term abdominal drain group vs 11% (2/19) in the large-volume paracentesis group; peritonitis incidence was 6% (1/17) vs 11% (2/19) respectively. Questionnaires/interview uptake/completion were ≥80%; interviews indicated that long-term abdominal drains could transform the care pathway. CONCLUSIONS: The REDUCe study demonstrates feasibility with preliminary evidence of long-term abdominal drain acceptability/effectiveness/safety and reduction in health resource utilisation. TRIAL REGISTRATION: ISRCTN30697116, date assigned: 07/10/2015.
引用
- Macken L, Bremner S, Gage H, et al. Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis. Aliment Pharmacol Ther. 2020. PMID: 32478917. doi:10.1111/apt.15802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。